US · Healthcare · Diagnostics & Research
EPS came in at 0.17 against a street estimate of 0.06 — a beat of 183.3%.
Analysts rate CareDx Inc a buy (5 buy, 3 hold, 0 sell out of 8) with an average price target of $43.67.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.74% |
| BAMCO Inc | 6.45% |
| State Street Corp | 5.34% |
| ARK Investment Management LLC | 4.31% |
| Deerfield Management Co | 4.24% |
| BRAIDWELL LP | 4.20% |
| Vanguard Capital Management, LLC | 4.18% |
| Boston Partners Global Investors, Inc | 3.64% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 | 2026-07-30 |
| Results announced · Q3 2026 | 2026-07-30 |
| Acquisition completed · Q2 2026 | 2026-07-07 |
| Board / officer change · Q2 2026 | 2026-06-15 |
| Quarterly report · Q1 2026 | 2026-04-28 |
| Results announced · Q2 2026 | 2026-04-28 |
| Proxy statement · Q2 2026 | 2026-04-27 |
| Annual report FY2025 | 2026-02-25 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for CareDx Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.